Tiroid ve karaciğer

Karaciğer tiroid hormonlarının metabolizmasında önemli bir rol oynamaktadır. Bu nedenle karaciğer hastalıklarında tiroid bezi fonksiyonları etkilenmektedir. Özellikle otoimmün manifestasyonlar hepatit C virüsü infeksiyonu seyrinde gelişebilmekte, interferon tedavisi tiroid disfonksiyonuna yol açabilmektedir. Bunun aksine tiroid hastalıkları da karaciğerin morfolojik ve fonksiyonel yapısında değişimlere neden olabilmektedir. Diğer yandan antitiroid tedavi esnasında hepatotoksisite gelişebilmektedir. Bu yazıda tiroid ve karaciğer arasındaki ilişkiler incelenmiştir.

Tyhroid and liver

Background.- The liver has an important role in the metabolism of thyroid hormones. Therefore, thyroid functions may be affected by liver diseases. Especially, autoimmune thyroid manifestations can develop during hepatitis C virus infection, and interferon therapy can induce thyroid dysfunctions. Conversely, thyroid diseases may cause alterations in liver morphology and functions. Moreover, hepatotoxicity can evolve during antithyroid therapy. In this paper relationships between thyroid and liver were reviewed.

PDF

___

1. Sellin JH, Vasilopoulou-Sellin R. The gastrointestinal tract and liver in thyrotoxicosis. In Brauerman LE, Utiger RD. eds. Werner&Ingbar’s the Thyroid: A fundamental and clinical text. 8th ed. Philadelphia, Lippincott Williams&Wilkins, 2000; 622-26.
2. Sheridan P. Thyroid hormones and the liver. Clin Gastroenterol 1983; 12: 797-818.
3. Reyes H, Levi AJ, Gatmaitan Z, Arias IM. Studies of Y and Z, two hepatic cytoplasmic organic anion-binding proteins: effect of drugs, chemicals, hormones, and cholestasis. J Clin Invest 1971; 50: 2242-52.
4. Gartner LM, Arias IM. Hormonal control of hepatic bilirubin transport and conjugation. Am J Physiol 1972; 222: 1091-9.
5. Van Steenbergen W, Fevery J, De Groote J. Thyroid hormones and the hepatic handling of bilirubin. II. Effects of hypothyroidism and hyperthyroidism on the apparent maximal biliary secretion of bilirubin in the Wistar rat. J Hepatol 1988; 7: 229-38.
6. Layden TJ, Boyer JL. The effect of thyroid hormone on bile salt-independent bile flow and Na+, K+ -ATPase activity in liver plasma membranes enriched in bile canaliculi. J Clin Invest 1976; 57: 1009-18.
7. Van Steenbergen W, Fevery J, De Vos R, Leyten R, Heirwegh KP, De Groote J. Thyroid hormones and the hepatic handling of bilirubin. I. Effects of hypothyroidism and hyperthyroidism on the hepatic transport of bilirubin mono- and diconjugates in the Wistar rat. Hepatology 1989; 9: 314-21.
8. Iossa S, Liverini G, Barletta A. Relationship between the resting metabolic rate and hepatic metabolism in rats: effect of hyperthyroidism and fasting for 24 hours. J Endocrinol 1992; 135: 45-51.
9. Magnusson I, Wennlund A, Chandramouli V, et al. Fructose-6-phosphate cycling and the pentose cycle in hyperthyroidism. J Clin Endocrinol Metab 1990; 70: 461-6.
10. Gebhard RL, Stone BG, Andreini JP, Duane WC, Evans CD, Prigge W. Thyroid hormone differentially augments biliary sterol secretion in the rat. I. The isolated-perfused liver model. J Lipid Res 1992; 33: 1459-66.
11. Sellin JH, Vasilopoulou-Sellin R. The gastrointestinal tract and liver in hypothyroidism. In Brauerman LE, Utiger RD. eds. Werner&Ingbar’s the Thyroid: A fundamental and clinical text. 8th ed. Philadelphia, Lippincott Williams&Wilkins, 2000; 795-99.
12. Pauletzki J, Stellaard F, Paumgartner G. Bile acid metabolism in human hyperthyroidism. Hepatology 1989; 9: 852-5.
13. Babb RR. Associations between diseases of the thyroid and the liver. Am J Gastroenterol 1984; 79: 421-3.
14. Huang MJ, Liaw YF. Clinical associations between thyroid and liver diseases. J Gastroenterol Hepatol 1995; 10: 344-50.
15. Huang MJ, Liaw YF. Thyroxine-binding globulin in patients with chronic hepatitis B virus infection: different implications in hepatitis and hepatocellular carcinoma. Am J Gastroenterol 1990; 85: 281-4.
16. Ross DS, Daniels GH, Dienstag JL, Ridgway EC. Elevated thyroxine levels due to increased thyroxinebinding globulin in acute hepatitis. Am J Med 1983; 74:564-9.
17. L'Age M, Meinhold H, Wenzel KW, Schleusener H. Relations between serum levels of TSH, TBG, T4, T3, rT3 and various histologically classified chronic liver diseases. J Endocrinol Invest 1980; 3: 379-83.
18. Gardner DF, Carithers RL Jr, Utiger RD. Thyroid function tests in patients with acute and resolved hepatitis B virus infection. Ann Intern Med 1982; 96: 450-2.
19. Van Thiel DH, Smith WI Jr, Wight C, Abuid J. Elevated basal and abnormal thyrotropin-releasing hormoneinduced thyroid-stimulating hormone secretion in chronic alcoholic men with liver disease. Alcohol Clin Exp Res 1979; 3: 302-8.
20. Chopra IJ, Solomon DH, Chopra U, Young RT, Chua Teco GN. Alterations in circulating thyroid hormones and thyrotropin in hepatic cirrhosis: Evidence for euthyroidism despite subnormal serum triiodothyronine. J Clin Endocrinol Metab 1974; 39: 501-11.
21. Schlienger JL. Thyroid status in fifty patients with alcoholic cirrhosis. Z Gasteroenterol 1979; 17: 452-61.
22. Ain KB, Refetoff S. Relationship of oligosaccharide modification to the cause of serum thyroxine-binding globulin excess. J Clin Endocrinol Metab 1988; 66:1037-43
23. Nomura S, Pittman CS, Chambers JB Jr, Buck MW, Shimizu T. Reduced peripheral conversion of thyroxine to triiodothyronine in patients with hepatic cirrhosis. J Clin Invest 1975; 56: 643-52.
24. Faber J, Thomsen HF, Lumholtz IB, Kirkegaard C, Siersbaek-Nielsen K, Friis T. Kinetic studies of thyroxine, 3,5,3'-triiodothyronine, 3,3,5'-triiodothyronine, 3', 5'-diiodothyronine, 3,3'-diiodothyronine, and 3'- monoiodothyronine in patients with liver cirrhosis. J Clin Endocrinol Metab 1981; 53: 978-84.
25. Chopra IJ. An assessment of daily production and significance of thyroidal secretion of 3, 3', 5'- triiodothyronine (reverse T3) in man. J Clin Invest 1976;58: 32-40.
26. Deutsch M, Dourakis S, Manesis EK, Gioustozi A, Hess G, Horsch A, Hadziyannis S. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 1997; 26: 206-10.
27. Marine D, Lenhart CH. Pathological anatomy of exophthalmic goiter: The anatomical and physiological relations of the thyroid gland to the disease; the treatment. Arch Intern Med 1911; 8:265-316.
28. Beaver DC, Pemberton J deJ. The pathologic anatomy of the liver in exophthalmic goiter. Ann Intern Med 1933; 7:687-708.
29. Cameron GR, Karuntaratne WAE. Liver changes in exophthalmic goiter. J Path Bact 1935; 41: 267-93.
30. Moschcowitz E. Pathogenesis of cirrhosis of the liver occurring in patients with diffuse toxic goiter. Arch Intern Med 1946; 78: 497-530.
31. Piper J, Paulsen E: Liver biopsy in thyrotoxicosis. Acta Med Scand 1947; 127: 439-45.
32. Movitt ER, Gerstl B, Davis AE. Needle liver biopsy in thyrotoxicosis. Arch Intern Med 1953; 91: 729-39.
33. Klion FM, Segal R, Schaffner F. The effect of altered thyroid function on the ultrastructure of the human liver. Am J Med 1971; 50: 317-24.
34. Sheridan P. Thyroid hormones and the liver. Clin Gastroenterol 1983; 12:797-818.
35. Huang MJ, Liaw YF. Clinical associations between thyroid and liver diseases. J Gastroenterol Hepatol 1995; 10: 344-50.
36. Fong TL, McHutchison JG, Reynolds TB. Hyperthyroidism and hepatic dysfunction. A case series analysis. J Clin Gastroenterol 1992; 14: 240-4.
37. Lorenz G, Meng W. Bioptical liver changes in florid hyperthyreosis. Acta Hepatogastroenterol 1975; 22: 22-5.
38. Klion FM, Segal R, Schaffner F: The effect of altered thyroid function on the ultrastructure of the human liver Am J Med 1971; 50: 317-324.
39. Sola J, Pardo-Mindan FJ, Zozaya J, Quiroga J, Sangro B, Prieto J. Liver changes in patients with hyperthyroidism Liver 1991; 11: 193-7.
40. Imberti R, Vairetti M, Gualea MR, Feletti F, Poma G, Richelmi P, Preseglio I, Bellomo G. The effects of thyroid hormone modulation on rat liver injury associated with ischemia-reperfusion and cold storage. Anesth Analg 1998; 86: 1187-93.
41. Huang MJ, Li KL, Wei JS, Wu SS, Fan KD, Liaw YF. Sequential liver and bone biochemical changes in hyperthyroidism: prospective controlled follow-up study. Am J Gastroenterol 1994; 89: 1071-6.
42. Dooner HP, Parada J, Aliaga C, Hoyl C. The liver in thyrotoxicosis. Arch Intern Med 1967; 120: 25-32.
43. Greenberger WJ, Milligan FD, DeGroot LJ, Isselbacher KJ. Jaundice and thyrotoxicosis in the absence of conestive heart failure. Am J Med 1964; 36: 840-6.
44. Chen F. Liver function in thyrotoxicosis. J Formosan Med Assoc 1963; 62: 130-9.
45. Thompson P Jr, Strum D, Boehm T, Wartofsky L. Abnormalities of liver function tests in tyrotoxicosis Mil Med 1978; 143: 548-51.
46. Gerlach U, Paul L, Latzel H. Isoenzymes of alkaline phosphatase in hyperthyroidism. Enzymol Biol Clin 1970; 11: 251-6.
47. Ashkar FS, Miller R, Smoak WM 3rd, Gilson AJ. Liver disease in hyperthyroidism. South Med J 1971; 64: 462-5.
48. Cooper DS, Kaplan MM, Ridgway EC, Maloof F, Daniels GH. Alkaline phosphatase isoenzyme patterns in hyperthyroidism. Ann Intern Med 1979; 90: 164-8.
49. Azizi F. gamma-Glutamyl transpeptidase levels in thyroid disease. Arch Intern Med 1982; 142: 79-81.
50. Yao JD, Gross JB Jr, Ludwig J, Purnell DC. Cholestatic jaundice in hyperthyroidism. Am J Med 1989; 86: 619-20.
51. Mosekilde L, Melsen F, Bagger JP, Myhre-Jensen O, Schwartz Sorensen N. Bone changes in hyperthyroidism: interrelationships between bone morphometry, thyroid function and calcium-phosphorus metabolism. Acta Endocrinol 1977; 85: 515-25.
52. Barnes SC, Wicking JM, Johnston JD. Graves' disease presenting with cholestatic jaundice. Ann Clin Biochem 1999; 36: 677-9.
53. Schussler GC, Schaffner F, Korn F. Increased serum thyroid hormone binding and decreased free hormone in chronic active liver disease. N Engl J Med 1978; 299:510-5.
54. Sato N, Ohira H, Orikasa H, et al. Primary biliary cirrhosis associated with painless thyroiditis. Intern Med 1999; 38: 244-8.
55. Culp KS, Fleming CR, Duffy J, Baldus WP, Dickson ER. Autoimmune associations in primary biliary cirrhosis. Mayo Clin Proc 1982; 57: 365-70.
56. Crowe JP, Christensen E, Butler J, et al. Primary biliary cirrhosis: The prevalence of hypothyroidism and its relationship to thyroid autoantibodies and sicca syndrome. Gastroenterology 1980; 78: 1437-41.
57. Thompson NP, Leader S, Jamieson CP, Burnham WR, Burroughs AK. Reversible jaundice in primary biliary cirrhosis due to hyperthyroidism. Gastroenterology 1994; 106: 1342-3.
58. Klein I, Levey GS. Unusual manifestations of hypothyroidism. Arch Intern Med 1984; 144: 123-8.
59. Paradies G, Ruggiero FM, Dinoi P. The influence of hypothyroidism on the transport of phosphate and on the lipid composition in rat-liver mitochondria. Biochim Biophys Acta 1991; 1070: 180-6.
60. Soboll S. Long-term and short-term changes in mitochondrial parameters by thyroid hormones. Biochem Soc Trans 1993; 21: 799-803.
61. Liverini G, Iossa S, Barletta A. Relationship between resting metabolism and hepatic metabolism: effect of hypothyroidism and 24 hours fasting. Horm Res 1992; 38: 154-9.
62. Comte B, Vidal H, Laville M, Riou JP. Influence of thyroid hormones on gluconeogenesis from glycerol in rat hepatocytes: a dose-response study. Metabolism 1990; 39: 259-63.
63. Marchesini G, Fabbri A, Bianchi GP, et al. Hepatic conversion of amino nitrogen to urea nitrogen in hypothyroid patients and upon L-thyroxine therapy. Metabolism 1993; 42: 1263-9.
64. Clancy RL, Mackay IR. Myxoedematous ascites. Med J Aust 1979; 2: 415-6.
65. Baker A, Kaplan M, Wolfe H. Central congestive fibrosis of the liver in myxedema ascites. Ann Intern Med 1972; 77: 927-9.
66. de Castro F, Bonacini M, Walden JM, Schubert TT. Myxedema ascites. Report of two cases and review of the literature. J Clin Gastroenterol 1991; 13: 411-4.
67. Agnello V, De Rosa FG. Extrahepatic disease manifestations of HCV infection: Some current issues. J Hepatol 2004; 40: 341-52.
68. Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 1999; 42: 2204-12.
69. Lunel F, Cacoub P. Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection. J Hepatol 1999; 31 Suppl 1: 210-6.
70. Duclos-Vallee JC, Johanet C, Trinchet JC, et al. High prevalence of serum antibodies to hepatitis C virus in patients with Hashimoto's thyroiditis. BMJ 1994; 309: 846-7.
71. Bisot-Locard S, Bornet H, Rousset H, Cortey-Boennec L, Bonnevial L, Vindimian M, Trepo C Low prevalence of antibodies to hepatitis C virus in patients with Hashimoto's thyroiditis. J Hepatol 1995; 23: 233-4.
72. Tran A, Quaranta JF, Benzaken S, et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology 1993; 18: 253-7.
73. Pateron D, Hartmann DJ, Duclos-Vallee JC, Jouanolle H, Beaugrand M. Latent autoimmune thyroid disease in patients with chronic HCV hepatitis. J Hepatol 1992; 16: 244-5.
74. Pawlotsky JM, Ben Yahia M, Andre C, et al. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 1994; 19: 841-8.
75. Antonelli A, Ferri C, Pampana A, et al. Thyroid disorders in chronic hepatitis C. Am J Med 2004; 117: 10-3.
76. Antonelli A, Ferri C, Fallahi P. Thyroid cancer in patients with hepatitis C infection. JAMA 1999; 281: 1588.
77. Antonelli A, Ferri C, Fallahi P, Nesti C, Zignego AL, Maccheroni M. Thyroid cancer in HCV-related mixed cryoglobulinemia patients. Clin Exp Rheumatol. 2002; 20: 693-6.
78. Montella M, Pezzullo L, Crispo A, et al. Risk of thyroid cancer and high prevalence of hepatitis C virus. Oncol Rep 2003; 10: 133-6.
79. Watanabe U, Hashimoto E, Hisamitsu T, Obata H, Hayashi N. The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. Am J Gastroenterol 1994; 89: 399-403.
80. Roti E, Minelli R, Giuberti T, et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med 1996; 101: 482-7.
81. Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F, et al. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med 1998; 158: 1445-8.
82. Lisker-Melman M, Di Bisceglie AM, Usala SJ, Weintraub B, Murray LM, Hoofnagle JH. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 1992; 102: 2155-60.
83. Marcellin P, Pouteau M, Benhamou JP. Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction. J Hepatol 1995; 22: 364-9.
84. Ward DL, Bing-You RG. Autoimmune thyroid dysfunction induced by interferon-alpha treatment for chronic hepatitis C: screening and monitoring recommendations. Endocr Pract 2001; 7: 52-8.
85. Marcellin P, Pouteau M, Benhamou JP. Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction. J Hepatol 1995; 22: 364-9.
86. Kiehne K, Kloehn S, Hinrichsen H, Gallwitz B, Monig H. Thyroid autoantibodies and thyroid dysfunction during treatment with interferon-alpha for chronic hepatitis C. Endocrine 1997; 6: 231-4.
87. Preziati D, La Rosa L, Covini G, et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol 1995; 132: 587-93.
88. Cooper DS. Antithyroid drugs for the treatment of hyperthyroidism caused by Graves' disease. Endocrinol Metab Clin North Am 1998; 27: 225-47.
89. Cooper DS, Goldminz D, Levin AA, et al. Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. Ann Intern Med 1983; 98: 26-29.
90. Zimmerman HJ. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals an the Liver. 2nd ed. Philadelphia, Lippincott Williams&Wilkins, 1999; 555-588.
91. Liaw YF, Huang MJ, Fan KD, Li KL, Wu SS, Chen TJ. Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism. A cohort study. Ann Intern Med 1993; 118: 424-8.
92. Vitug AC, Goldman JM. Hepatotoxicity from antithyroid drugs. Horm Res 1985; 21: 229-34.
93. Williams KV, Nayak S, Becker D, Reyes J, Burmeister LA. Fifty years of experience with propylthiouracilassociated hepatotoxicity: what have we learned? J Clin Endocrinol Metab 1997; 82: 1727-33.
94. Gotta AW, Sullivan CA, Seaman J, Jean-Gilles B. Prolonged intraoperative bleeding caused by propylthiouracil-induced hypoprothrombinemia. Anesthesiology 1972; 37: 562-3.
95. Blom H, Stolk J, Schreuder HB, von Blomberg-van der Flier M. A case of carbimazole-induced intrahepatic cholestasis. An immune-mediated reaction? Arch Intern Med 1985; 145: 1513-5.
96. Arab DM, Malatjalian DA, Rittmaster RS. Severe cholestatic jaundice in uncomplicated hyperthyroidism treated with methimazole. J Clin Endocrinol Metab 1995; 80: 1083-5.
97. Kang H, Choi JD, Jung IG, et al. A case of methimazoleinduced acute hepatic failure in a patient with chronic hepatitis B carrier. Korean J Intern Med 1990; 5: 69-73.